Enzymatic mutation detection method evaluated for detection of p53 mutations in cDNA from breast cancers

Clinical Chemistry

Volumn 47, Issue 5, 2001, Pages 821-828

  Norberg, T ^a   Klaar, S ^a   Lindqvist, L ^a   Lindahl, T ^a   Ahlgren, J ^a   Bergh, J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA;

ARTICLE; AUTOANALYZER; BREAST CANCER; BREAST CARCINOGENESIS; CANCER SURVIVAL; COMPUTER PROGRAM; CONTROLLED STUDY; GENE MUTATION; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; PROGNOSIS; RELIABILITY; TUMOR SUPPRESSOR GENE;

EID: 0035043023     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/47.5.821     Document Type: Article

References (22)

1. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
2. Clinical implications of the p53 gene
3. Clonal expansion of p53 mutant cells in associated with brain tumour progression
4. p53, guardian of the genome
5. Prognostic significance of TP53 alterations in breast carcinoma
6. Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols
7. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
8. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
9. p53 alterations in all stages of breast cancer
10. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry
11. Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors
12. Subgroups of p53 mutations may predict the clinical behaviour of cancers in the breast and colon and contribute to therapy response
13. Automated fluorescent analysis procedure for enzymatic mutation detection
14. Evaluation of enzymatic mutation detection trademark in hereditary nonpolyposis colorectal cancer
15. Enzymatic mutation detection (EMD™) of novel mutations (R565X and R1523X) in the FBN1 gene of patients with Marfan syndrome using T4 endonuclease
16. Analysis of the hereditary pancreatitis-associated cationic trypsinogen gene mutations in exons 2 and 3 by enzymatic mutation detection from a single 2.2-kb polymerase chain reaction product
17. Enzymatic mutation detection. Phosphate ions increase incision efficiency of endonuclease VII at a variety of damage sites in DNA
18. Enzymatic mutation detection in the p53 gene
19. Sequencing with microarray technology - A powerful new tool for molecular diagnostics
20. Establishment and characterization of two neoplastic cell lines (U-1285 and U-1568) derived from small cell carcinoma of the lung
21. Breast tumor cell lines from pleural effusions
22. Assessment of sequence-based p53 gene analysis in human breast cancer: Messenger RNA in comparison with genomic DNA targets